Publikationen

Nach Jahr filtern

Nach Typ filtern

Nach Jahr filtern

Alle Jahre anzeigen

Entwicklung neuer Messinstrumente zur Erfassung von Cumulative Life Course Impairments (CLCI) bei chronisch-entzündlichen Hautkrankheiten

C. Braren-von Stülpnagel, M. Augustin, L. Westphal, R. Sommer

Poster presented at the 52. Jahrestagung der Deutschen Dermatologischen Gesellschaft (DDG-Tagung), Berlin, Germany.

Shared decision making for psoriasis systemic treatment from the patients' and the physicians' perspectives: Associations with sources of health information and health literacy

N. da Silva, M. Augustin, J. Traxler, R. Sommer

Poster presented at the 52. Jahrestagung der Deutschen Dermatologischen Gesellschaft (DDG-Tagung), Berlin, Germany.

Interventionen gegen Selbst-Stigmatisierung bei Personen mit sichtbaren chronischen Hauterkrankungen - ein systematischer Review

J. Traxler, L. Westphal, H. Graf, CFZ. Stuhlmann, R. Sommer

Poster presented at the 52. Jahrestagung der Deutschen Dermatologischen Gesellschaft (DDG-Tagung), Berlin, Germany.

A Comparative Analysis of the Predictors, Extent and Impacts of Self-stigma in Patients with Psoriasis and Atopic Dermatitis

S. Schlachter, R. Sommer, M. Augustin, A. Tsianakas & L. Westphal

The impact of dermatological diseases goes beyond symptoms and often includes psychosocial burden. Self-stigmatization plays a key role in this relationship and was compared in patients with psoriasis and atopic dermatitis to evaluate the validity of cross-disease stigmatization models. In total, 101 patients per indication were included in this cross-sectional study. Besides sociodemographic and clinical data, patient-reported outcome measures relating to self-stigmatization, depression, anxiety, and quality of life were compared across groups. Sociodemographic and clinical factors were tested for their moderating effects between self-stigmatization and quality of life.

PMID:
37014270
DOI:
https://doi.org/10.2340/actadv.v103.3962

Randomisierte, kontrollierte Interventionsstudie zur Entstigmatisierung von Menschen mit Hauterkrankungen: Erste Ergebnisse in gesundheitsnahen Berufen

J. Traxler, M. Augustin, M. Grosser, C. Braren-von Stülpnagel, R. Sommer

Poster presented at the 52. Jahrestagung der Deutschen Dermatologischen Gesellschaft (DDG-Tagung), Berlin, Germany.

Identifying Predictors and Correlates of Skin Disease Self-Stigma for Online RCT Intervention: A systematic review

CFZ. Stuhlmann, J. Traxler, V. Paucke, R. Sommer

Poster presented at the 52. Jahrestagung der Deutschen Dermatologischen Gesellschaft (DDG-Tagung), Berlin, Germany.

Psychosocial health and quality of life in ICSI and naturally conceived adolescents: a cross-sectional comparison

N. Eisemann, M. Schnoor, E. Rakuska, C.C. Braren-von Stülpnagel, A. Katalinic, M. Ludwig, B. Sonntag, A.K. Ludwig & S.A. Elsner

Psychosocial health and quality of life in ICSI and naturally conceived adolescents: a cross-sectional comparison

PMID:
36928650
DOI:
https://doi.org/10.1007/s11136-023-03382-5

Patient-reported Well-being in Value-based Care Using Tildrakizumab in a Real-world Setting: Protocol of a Multinational, Phase IV, 1-cohort Prospective Observational Study (the POSITIVE Study)

M. Augustin, R. Sommer, E. Daudén, P. Laws, E. de Jong, G. Fabbrocini, L. Naldi, A. Navarini, J. Lambert, Z. Reguiai, S. Gerdes, E. Massana, T. Obis, I. Kasujee & U. Mrowietz

Psoriasis is a chronic inflammatory skin disease that negatively impacts the quality of life of patients and their families. However, the most commonly used decision-making tools in psoriasis, Psoriasis Area and Severity Index (PASI), Physician Global Assessment (PGA) and Dermatology Life Quality Index (DLQI), do not fully capture the impact of psoriasis on patients' lives. In contrast, the well-established 5-item WHO Well-being Index (WHO-5) assesses the subjective psychological well-being of patients. Moreover, while drug innovations became available for psoriasis, data on the impact of these therapies on patients' lives and their closest environment (family, physicians) are limited. This study will assess the effect of tildrakizumab, an interleukin-23p19 inhibitor, on the overall well-being of patients with moderate-to-severe psoriasis. Moreover, the long-term benefit of tildrakizumab on physicians' satisfaction and partners' lives of patients with psoriasis will be evaluated.

PMID:
36792337
DOI:
https://doi.org/10.1136/bmjopen-2021-060536

Out-of-Pocket Costs in Alopecia Areata: A Cross-Sectional Study in German-speaking Countries

J. Kullab, MC. Schielein, CFZ. Stuhlmann, L. Tizek, H. Wecker, A. Kain,  T. Biedermann, & A. Zink

Alopecia areata is a common skin disease which is associated with psychosocial and financial burden. No curative therapy exists and, hence, affected persons resort to self-financed cosmetic solutions. However, studies on the economic impact of alopecia areata on individuals are limited. To estimate annual individual out-of-pocket costs in persons with alopecia areata, a cross-sectional study using a standardized online questionnaire was performed in Germany, Austria and Switzerland. 

PMID:
36598280
DOI:
https://doi.org/10.2340/actadv.v103.4441

Development and validation of a measuring instrument for dry skin - the Xerosis Area and Severity Index (XASI)

R. Sommer, M. Augustin, N. da Silva, C. Braren-von Stülpnagel

Poster presented at the 52. Jahrestagung der Deutschen Dermatologischen Gesellschaft (DDG-Tagung), Berlin, Germany.

<< < 1 2 3 4 5 6 … 18 > >>